PRL3-zumab not checked

Intra-IMMUSG Pte Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“PRL3-zumab will be administered every 2-week/dose till patient progress or develops intolerable toxicity or withdraw consent. A dose at 10-days is allowed at the first 4 doses when patients had heavier tumor burden since PRL3-zumab PK t ½ = 12 days (±2 days).”In the company’s words, NCT07290088 on ClinicalTrials.gov
Tested for
Advanced Solid Cancers, Advanced Malignant Solid Tumor, Solid Tumor, Neovascular Age Related Macular Degeneration
Main trialPhase 2/3
“This is a Multi-Center, Phase II/III, open-label, single dose level (6 mg/kg) basket trial of PRL3-zumab monotherapy in solid cancer patients. The study will consist of a Screening Period (Day - 14 to Day -1) for completion of all screening assessments before the first administration of study treatment, a Treatment Period during which visits will occur every 2-week (PK T1/2 = 12 days ±2 days), once the decision to discontinue treatment for any reason, an End of Treatment (EOT) visit will be performed within 14 days ±4 days after last dose of study treatment. Safety Follow-up/EOS visit will…”In the company’s words, NCT07290088 on ClinicalTrials.gov

Other drugs for Advanced Solid Cancers

All 9 drugs for Advanced Solid Cancers

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting Dec 2026 Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Phase 2Active, not recruiting 1 Jun 2026 PRL3-Zumab in Patients With Advanced Solid Tumors
Phase 2Active, not recruiting 1 Dec 2026 A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Phase 1/2Recruiting 7 Feb 2027 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PRL3-zumab

Following is part of Solo: you see every change to PRL3-zumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in